These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 35870026)

  • 61. Acetylcholine Receptor Antibody Titers and Clinical Course after Influenza Vaccination in Patients with Myasthenia Gravis: A Double-Blind Randomized Controlled Trial (ProPATIent-Trial).
    Tackenberg B; Schneider M; Blaes F; Eienbröker C; Schade-Brittinger C; Wellek A; Deschauer M; Eickmann M; Klenk HD; Müller HH; Sommer N
    EBioMedicine; 2018 Feb; 28():143-150. PubMed ID: 29337134
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Case Report: Acquired Haemophilia A Following mRNA-1273 Booster Vaccination Against SARS-CoV-2 With Concurrent Diagnosis of Pleomorphic Dermal Sarcoma.
    Plüß M; Mitteldorf C; Szuszies CJ; Tampe B
    Front Immunol; 2022; 13():868133. PubMed ID: 35479071
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Medium-term impact of the SARS-CoV-2 mRNA vaccine against disease activity in patients with systemic lupus erythematosus.
    Yoshida T; Tsuji H; Onishi A; Takase Y; Shirakashi M; Onizawa H; Hiwa R; Kitagori K; Akizuki S; Nakashima R; Tanaka M; Yoshifuji H; Morinobu A
    Lupus Sci Med; 2022 Aug; 9(1):. PubMed ID: 35961691
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose.
    Nevo L; Cahen-Peretz A; Vorontsov O; Frenkel R; Kabessa M; Cohen SM; Hamrani A; Oiknine-Djian E; Lipschuetz M; Goldman-Wohl D; Walfisch A; Kovo M; Neeman M; Yagel S; Wolf DG; Beharier O
    Am J Obstet Gynecol; 2022 Sep; 227(3):486.e1-486.e10. PubMed ID: 35430228
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Thyrotoxicosis following SARS-COV-2 vaccination: a case series and discussion.
    Pla Peris B; Merchante Alfaro AÁ; Maravall Royo FJ; Abellán Galiana P; Pérez Naranjo S; González Boillos M
    J Endocrinol Invest; 2022 May; 45(5):1071-1077. PubMed ID: 35015288
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19.
    Hofstadt-van Oy U; Stankovic S; Kelbel C; Oswald D; Larrosa-Lombardi S; Barchfeld T; Cleff U
    J Neurol; 2021 Sep; 268(9):3125-3128. PubMed ID: 33537898
    [TBL] [Abstract][Full Text] [Related]  

  • 67. SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease.
    Wagner A; Garner-Spitzer E; Schötta AM; Orola M; Wessely A; Zwazl I; Ohradanova-Repic A; Weseslindtner L; Tajti G; Gebetsberger L; Kratzer B; Tomosel E; Kutschera M; Tobudic S; Pickl WF; Kundi M; Stockinger H; Novacek G; Reinisch W; Zielinski C; Wiedermann U
    Front Immunol; 2022; 13():889138. PubMed ID: 35634285
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Safety of SARS-CoV-2 vaccines in patients with myasthenia gravis: a meta-analysis.
    Zheng Q; Cheng Y; Song C; Feng Z; Xu Z
    Neurol Sci; 2023 Sep; 44(9):2999-3003. PubMed ID: 37243794
    [No Abstract]   [Full Text] [Related]  

  • 69. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
    Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE
    Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies.
    Dalakas MC
    Curr Opin Neurol; 2020 Oct; 33(5):545-552. PubMed ID: 32833750
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.
    Schrezenmeier E; Bergfeld L; Hillus D; Lippert JD; Weber U; Tober-Lau P; Landgraf I; Schwarz T; Kappert K; Stefanski AL; Sattler A; Kotsch K; Dörner T; Sander LE; Budde K; Halleck F; Kurth F; Corman VM; Choi M
    Front Immunol; 2021; 12():690698. PubMed ID: 34276681
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A Case Report and Literature Review of New-Onset Myasthenia Gravis After COVID-19 Infection.
    Chatterjee T; Senthil Kumaran S; Roy M
    Cureus; 2022 Dec; 14(12):e33048. PubMed ID: 36721575
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Letter to the Editor on "New-Onset Myasthenia Gravis Confirmed by Electrodiagnostic Studies After a Third Dose of SARS-CoV-2 mRNA-1273 Vaccine".
    Kim S; Eun MY; Seok HY
    Am J Phys Med Rehabil; 2023 Jul; 102(7):e102. PubMed ID: 36762834
    [No Abstract]   [Full Text] [Related]  

  • 74. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
    Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI
    Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Electronic health record derived-impact of COVID-19 on myasthenia gravis.
    Roy B; Kovvuru S; Nalleballe K; Onteddu SR; Nowak RJ
    J Neurol Sci; 2021 Apr; 423():117362. PubMed ID: 33639420
    [No Abstract]   [Full Text] [Related]  

  • 76. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients.
    Gunji K; Skolnick C; Bednarczuk T; Benes S; Ackrell BA; Cochran B; Kennerdell JS; Wall JR
    Clin Immunol Immunopathol; 1998 Jun; 87(3):276-81. PubMed ID: 9646837
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
    Vincent A; Leite MI
    Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Factors affecting outcome in ocular myasthenia gravis.
    Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
    Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military.
    Montgomery J; Ryan M; Engler R; Hoffman D; McClenathan B; Collins L; Loran D; Hrncir D; Herring K; Platzer M; Adams N; Sanou A; Cooper LT
    JAMA Cardiol; 2021 Oct; 6(10):1202-1206. PubMed ID: 34185045
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents.
    Chelala L; Jeudy J; Hossain R; Rosenthal G; Pietris N; White CS
    AJR Am J Roentgenol; 2022 Apr; 218(4):651-657. PubMed ID: 34704459
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.